{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-002942","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.231046+00:00","generated_at":"2026-06-18T11:13:18.479104+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MaxCyte reports preliminary FY2022 revenue $44.3M (+31% YoY); guides 2023 growth 21-26%","bullets":["FY2022 total revenue ~$44.3M, up 31% from $33.9M in 2021; Q4 revenue ~$12.4M, up 22%.","Installed base >600 instruments (vs >500 end 2021); 18 SPL partnerships at year-end, 19 after Jan 2023.","2023 guidance: total revenue growth 21-26%, core growth 20-25%, SPL program-related revenue ~$6M.","Potential pre-commercial milestones under SPLs >$1.55B; 16 licensed clinical programs in clinic.","SPL program-related revenue in FY2022 was $4.6M vs $2.5M in 2021; Q4 included $1.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-002942","json":"https://secwatch.observer/filing/0001558370-23-002942.json","markdown":"https://secwatch.observer/filing/0001558370-23-002942.md","text":"https://secwatch.observer/filing/0001558370-23-002942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023002942/0001558370-23-002942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023002942/mxct-20230306x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:13:18.479104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}